Modulating Treg stability to improve cancer immunotherapy.
cancer immunotherapy
immunotolerance
lineage instability
regulatory T cells
tumor microenvironment
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
03
05
2023
revised:
23
07
2023
accepted:
25
07
2023
medline:
23
10
2023
pubmed:
20
8
2023
entrez:
19
8
2023
Statut:
ppublish
Résumé
Immunosuppressive regulatory T cells (Tregs) provide a main mechanism of tumor immune evasion. Targeting Tregs, especially in the tumor microenvironment (TME), continues to be investigated to improve cancer immunotherapy. Recent studies have unveiled intratumoral Treg heterogeneity and plasticity, furthering the complexity of the role of Tregs in tumor immunity and immunotherapy response. The phenotypic and functional diversity of intratumoral Tregs can impact their response to therapy and may offer new targets to modulate specific Treg subsets. In this review we provide a unifying framework of critical factors contributing to Treg heterogeneity and plasticity in the TME, and we discuss how this information can guide the development of more specific Treg-targeting therapies for cancer immunotherapy.
Identifiants
pubmed: 37598003
pii: S2405-8033(23)00142-5
doi: 10.1016/j.trecan.2023.07.015
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-927Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests R.Z. is inventor on patent applications related to work on GITR, PD-1, and CTLA-4. R.Z. is scientific advisory board member of iTEOS Therapeutics, has consulted for Leap Therapeutics, and receives grant support from AstraZeneca and Bristol Myers Squibb.